Empagliflozin (4) (Jardiance®) – Chronic heart failure (CHF) with preserved ejection fraction

Characteristics

Start date 01.04.2022
Resolution 15.09.2022
INN Empagliflozin
Brand name Jardiance®
Pharm. company Boehringer Ingelheim Pharma GmbH & Co. KG
G-BA procedure ID 2022-04-01-D-799
Therapeutic area Cardiovascular diseases
Reason for procedure New Indication

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Adults with symptomatic chronic heart failure (CHF) with preserved ejection fraction HFpEF (LVEF > 50%) and with mildly impaired ejection fraction HFmrEF (LVEF > 40 to 49%).

Subpopulation Indication Comparator
Adults with symptomatic chronic heart failure (CHF) with preserved ejection fraction HFpEF (LVEF > 50%) and with mildly impaired ejection fraction HFmrEF (LVEF > 40 to 49%). An optimised standard therapy for the treatment of symptomatic, chronic heart failure with preserved ejection fraction or slightly reduced ejection fraction and the underlying diseases, such as hypertension, cardiac arrhythmias, coronary heart disease, diabetes mellitus, chronic kidney disease, dyslipoproteinaemia as well as the accompanying symptoms.

9. Associated procedures



<< List of all resolutions